Gain Therapeutics - Unfolding the next generation of allosteric small molecule therapies to meet patient needs
-
Data shows restored motor function in mouse models of Parkinson’s disease
-
Dosing Underway for Phase 1 Parkinson Trial of GBA1-Targeting Agent GT-02287
-
Gain Therapeutics’ supercomputer-driven therapy offers potential Parkinson’s breakthrough
-
Gain's clinical Parkinson's drug restores motor function in mice
-
Insights on GBA1-Targeting Agent GT-02287 for Parkinson Disease: Joanne Taylor, PhD
-
Motor function restored in Parkinson’s mice with GT-02287
-
Swiss biotech restores motor function in mice with Parkinson’s disease